Drug Trial Radar · NCT03872453
Acute Treatment Trial in Adult Subjects With Migraines
Last checked: Nov 20, 2026Latest source record: Sep 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,154
Actual
Start
Mar 25, 2019
Primary completion
Oct 31, 2019
Study completion Nov 11, 2019
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Mar 13, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the safety and efficacy of three different intranasal dose levels of zavegepant (BHV-3500), relative to placebo, in the acute treatment of moderate to severe migraine.
Conditions
- Migraine
Interventions
ZavegepantDrug
A single dose of zavegepant
Zavegepant matching placeboDrug
A single dose of placebo matched to zavegepant
Intranasal Aptar Pharma Unit Dose SystemDevice
A single-dose intranasal device
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Freedom From Pain at 2 Hours Post-doseTime frame: 2 hours post-dose
- Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-doseTime frame: 2 hours post-dose
Locations
82 sites in 1 country. Site status is shown where the registry gives one.
Coastal Clinical Research, Inc.
Mobile, Alabama
Elite Clinical Studies
Phoenix, Arizona
Baptist Health Center for Clinical Research
Little Rock, Arkansas
Pharmacology Research Institute
Encino, California
eStudySite
La Mesa, California
Synergy San Diego
Lemon Grove, California
Collaborative Neuroscience Network, LLC
Long Beach, California
Pharmacology Research Institute
Los Alamitos, California
Pharmacology Research Institute
Newport Beach, California
National Research Institute
Panorama City, California
Optimus Medical Group
San Francisco, California
Neurological Research Institute
Santa Monica, California
Diablo Clinical Research, Inc.
Walnut Creek, California
Denver Neurological Research, LLC
Denver, Colorado
CT Clinical Research
Cromwell, Connecticut
Ki Health Partners, LLC, dba New England Institute for Clinical Research
Stamford, Connecticut
MD Clinical
Hallandale, Florida
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida
Multi-Specialty Research Associates, Inc.
Lake City, Florida
AGA Clinical Trials
Miami, Florida
Qps Mra, Llc
Miami, Florida
Clinical Neuroscience Solutions, Inc.
Orlando, Florida
Ormond Medical Arts Pharmaceutical Research Center
Ormond Beach, Florida
Meridien Research
Tampa, Florida
Premiere Research Institute
West Palm Beach, Florida
iResearch Atlanta, LLC
Decatur, Georgia
Meridian Clinical Research
Savannah, Georgia
Family Medicine Specialists/CIS
Wauconda, Illinois
Phoenix Medical Research
Prairie Village, Kansas
Crescent City Headache and Neurology Center, LLC
Chalmette, Louisiana
New Orleans Center for Clinical Research
New Orleans, Louisiana
DelRicht Research
New Orleans, Louisiana
Boston Clinical Trials
Boston, Massachusetts
Community Clinical Research Network
Marlborough, Massachusetts
Regeneris Medical
North Attleboro, Massachusetts
MedVadis Research Corporation
Watertown, Massachusetts
Michigan Head Pain & Neurological Institute
Ann Arbor, Michigan
Clinical Research Institute, Inc.
Minneapolis, Minnesota
Clinical Research Institute, Inc.
Plymouth, Minnesota
MedPharmics, LLC
Biloxi, Mississippi
Showing 40 of 82 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.